Compare Gilead Sciences, Inc. (GILD) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while GraniteShares 2x Long NVDA Daily ETF trades at $31.87. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals.
| GILD | NVDL | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $43.02 |
52-Week Low | $108.22 | $21.76 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $31.88, down 3.89% on the day, reflecting high volatility tied to its 2x leveraged exposure to NVIDIA. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI suggests potential overbought conditions. Recent stock splits on June 25-26, 2026, aim to improve liquidity. The ETF has delivered significant returns year-to-date (up 12.66% as of June 8, 2026, per 24/7 Wall Street) but remains vulnerable to sharp daily moves in NVIDIA.
The outlook for NVDL hinges entirely on NVIDIA's performance, offering amplified gains during AI-driven rallies but exposing investors to compounded losses during downturns. Key risks include daily reset mechanics, which can erode value in volatile markets, and dependence on a single stock. Investors seeking leveraged NVIDIA exposure must tolerate extreme volatility and monitor NVIDIA's earnings closely. The ETF suits aggressive traders betting on continued AI momentum but is unsuitable for long-term, risk-averse portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
